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Abstract
There are very different statistical methods for demonstrating a trend in pharmacological experi-
ments. Here, the focus is on sparse models with only one parameter to be estimated and interpreted:
the increase in the regression model and the difference to control in the contrast model. This provides
both p-values and confidence intervals for an appropriate effect size. A combined test consisting of the
Tukey regression approach and the multiple contrast test according to Williams is recommended, which
can be generalized to the generalized linear (mixed effect) model. Thus numerous variable types oc-
curring in pharmacology/toxicology can be adequately evaluated. Software is available through CRAN
packages. The most significant limitation of this approach is for designs with very small sample sizes,
often in pharmacology/toxicology.
The problem
One of the main statistical principles in pharmacology/toxicology is: ’Characterization of Dose-response
Relationships Inferred by Statistically Significant Trend Tests’ [30].
But the vast majority of articles on trend tests deal with time trends. Exactly this is not discussed here,
as the specific dependency between the times, e.g. 2014, 2015 and 2016, is modeled. Trends in dose-
response dependencies, recommended in guidelines, e.g. for in-vivo micronucleus assay [3], assume
independent doses in a randomized design (classification I). The dose is thus a grouped variable, e.g. 0,
10, 50 mg/kg, whereby the dose levels can be considered either as qualitative levels of a factor (analysis
of variance model) or quantitative values of a covariate (regression model) (or both; see below) (classi-
fication II). The essential classification depends on the objective, and this can be very different: simply
to show an increasing global trend, to estimate a specific dose, such as MED, NOAEL (in the sense of
Paracelsus) or using a model-based approach to estimate a lower confidence interval for a regulatory
defined dose, such as ED50 or the benchmark dose (BMD) (classification III). A related overview on
model-based approaches is available [36]. Some authors [29] argue to avoid trend test-based approaches
(NOAEL estimation) altogether because of their design dependency and to use the generally superior
model-based approaches, e.g. the BMDL (where L stands for lower confidence limit). Because of the
usually few doses, the small sample sizes, the non-interpolation, the critical model-assumption depen-
dence and the uncertainty of setting limits in BMD model, I would not prefer a BMDL of a NOAEL on
principle.
A misunderstanding between toxicologists and statisticians is the simple definition of what is actually a
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trend. Often trend tests are used which were formulated for linear trends, such as the Armitage trend
test [5] and the Jonckheere trend test [28]. But a specific shape of dose-response dependence is rarely
an a-priori assumption, but rather a result of the evaluation. Therefore, trend tests are needed which are
sensitive to as many shapes as possible, as well as supra- and sub-linear shapes, e.g. the common in
pharmacology/toxicology plateau-like shapes, and also allow a statement to be made as to which shape
of the alternative is most likely. We describe trend tests for near-to-linear trend, any shape trend, strictly
monotone trend and non-monotone trend, especially with down-turn effects at high doses (classification
VI).
Nowadays, the existence of a trend and its magnitude is usually represented by a p-value (or a derived
star). Its brevity and simplicity are bought at the expense of numerous serious disadvantages. Therefore,
the biologically relevant choice of an effect measure and its confidence interval is the better alternative.
For this purpose, the slope in 2-parametric regression models or the difference/ratio to control is particu-
larly suitable (classification V).
Numerous statistical tests are based on normally distributed homoscedastic error terms in a randomized
one-way layout. But in pharmacology/toxicology, many other endpoints such as proportions, counts,
time-to-events, etc. occur in more complex systems, including random terms such as within-litter depen-
dencies. One needs trend tests in the generalized linear model (GLM) and generalized linear mixed effect
model (GLMM). Also robust variants for any distribution and even informative variance heterogeneity,
e.g. increasing with effect increase (classification VI).
A basic idea is a model that is as simple (’spares’) as possible, which is realized by exactly one, inter-
pretable parameter, e.g. the slope in regression models or the difference to the control in contrast tests.
Of course you can find much better fitting models, e.g. polynomials, splines or 5-parametric nonlin-
ear models. But both their comparison across endpoints, sex, species, studies, relevant in pharmacol-
ogy/toxicology, and their biological interpretability are rather difficult (classification VII).
Limiting factors are the very small sample size per dose group ni common in pharmacology/toxicology,
up to the triplicates in the Ames assay, and the usually few dose levels (k=3+1): in terms of the false+/false-
decision ratio, model discrimination, robustness, etc. In practice, asymptotic tests are used (which assume
n → inf) and sometimes the bias is massive. There is no universal solution to this problem, but in some
places the mitigation of this limitation is pointed out.
Classification: (bold ... discussed here; italic ... not here)
I: independent dose groups in a randomized design vs. dependent time points
II: a) dose modeled qualitatively, b) dose modeled quantitatively, c) jointly
III: a) just claiming global trend, b) estimate NOAEL (MED), c) model-based estimation of ED50,
BMDL
IV: tests for a) near-to-linear trend, b) any shape trend, c) strictly monotone trend and d) non-
monotone trend (especially with down-turn effects at high doses)
V: avoid p-values. Use an appropriate effect measure and its confidence interval for interpreta-
tion
VI: a) trend tests in GLM, GLMM, b) robust trend tests
VII: using sparse models with preferably only one interpretable parameter
Motivating examples
Three data sets were selected. One from regulatory toxicology (repeated administration of sodium dichro-
mate dihydrate in a chronic study on rat), a second from environmental toxicology (aquatic assay using
ceriodaphnia dubia) and a third from veterinary pharmacology using beagle dogs. In the left panel of
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Figure 1 the number of total brood in ceriodaphnia dubia after treatment with increasing tank concentra-
tions of nitrofen [6] are show, in the middle panel the blood urea nitrogen (BUN) endpoint of the 13-week
study with sodium dichromate dihydrate [1] where a downturn effect at high dose occur, and in the right
panel are the 24 hours diuresis values for 0, 1, 2, and 4 mg/kg i.m. furosemide to treat congestive heart
failure in dogs [7]. The occurring data diversity is thus somewhat depicted. Increasing and decreasing
trends, monotone trends and those with downturn effects at high doses (and those with plateau effect),
counts and continuous endpoints, variance homogeneity and heterogeneity, designs with (k = 3 + 1),
(k = 4 + 1) and (k = 5 + 1):
Figure 1: Boxplots for example data: nitrofen (left), blood urea nitrogen (middle), furosemide (right)
Trend tests
Trend tests where dose is modeled qualitatively: multiple contrast tests
To consider the dose as a factor with qualitative levels seems absurd at first, since the dose levels are
known. However, the difference between the applied dose and the concentration at the target and the
assumptions-sparing modeling can be exactly that.
Due to the sparse model strategy (class. VII), only linear contrast tests are considered here. A contrast
is a suitable linear combination of means x¯i (or other effect sizes, such as ratio-to-control, odds ratio,
hazard ratio):
∑k
i=0 cix¯i, where the contrast coefficient ci are appropriate chosen weights. Specific
for all experiments in pharmacology/toxicology is the comparison to the control i = 0, ..., k. A single
contrast test is its standardized version tSingle contrast =
∑k
i=0 cix¯i/S
√∑k
i c
2
i /ni and
∑k
i=0 ci = 0
ensures a tdf,1−α distributed level-α-test. A multiple contrast test (MCT) is defined as maximum test
is: tMCT = max(t1, ..., tq) which follows jointly (t1, . . . , tq)′ a q-variate t- distribution with degree of
freedom df and the correlation matrix R⇒ depending on ci, ni but also si, ρi, ... and may be complex.
The choice of the weights ci and hence the particular contrast matrix defines the special version, e.g. for
a simple balanced design with k=2: Dunnett one-sided test [11]
ci C T1 T2
ca -1 0 1
cb -1 -1 0
Williams one-sided procedure (formulated as multiple contrast [8]) The simple Williams contrast
ci C D1 D2
ca -1 0 1
cb -1 1/2 1/2
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illustrates the idea and interoperability of an MCT: either the comparison of D2 vs. C is significant
(i.e. strict monotone), or to the pooled (D2 + D1)/2, i.e. a plateau (or both, or neither (H0). Either
multiplicity-adjusted p-values or simultaneous confidence limits (here one-side lower one) are available:
[
∑k
i=0 cix¯i − S ∗ tq,df,R,2−sided,1−α
√∑k
i c
2
i /ni] This makes the Williams test the recommended trend
test in pharmacology/toxicology: sensitive to some monotonic and partially non-monotonic forms, a com-
parison to the control, easily interpretable confidence intervals for the required effect sizes (difference of
proportions [20], risk ratio or odds ratio of proportions [21], ratio-to-control estimates [18], relative effect
sizes [31], hazard rates [15], multiple endpoints [14], heteroscedastic error terms [16], poly-k-adjusted
tumor rates [42]).
Sometimes the question arises whether to use the Dunnett-test (unrestricted H1) or the Williams-test
(restricted H1)? The simple answer is use both [26]: The slight increase in conservatism (correlated con-
ci C D1 D2
ca -1 0 1
cb -1 1 0
cc -1 1/2 1/2
trasts!) is usually overcompensated by the simultaneous interpretability of disordered or ordered effects.
Considering the doses as qualitative factor levels, the William test can be recommended
using the R-package multcomp
Trend tests where dose is modeled quantitatively: Tukey-type regression models
There are numerous approaches to the relationship between response and dose formulated as quantitative
covariates, but because of the sparse-model strategy quasilinear regression models are considered here
(Notice, The MCP-Mod approach, see below, can be seen as a linear regression with a single predictor
variable [48]). Tukey’s trend test [49] is close to pharmacological principles and quite simple: the si-
multaneous considering of three regression models for the metameters Di, (untransformed) rank(Di)
(ordinal-transformed) and log(Di) (lin-logarithmic transformed dose). This joint test represents also
max-T-test, where the joint distribution over these linear (generalized) models (instead of just contrasts)
is achieved by the multiple marginal model approach (mmm) [35] where a related CRAN package is
available [40].
Trend tests where dose is modeled jointly qualitatively and quantitatively
One can combine the advantages of both Williams (qualitative) and Tukey (quantitative) test by formu-
lating a related joint max-T test [24], since both models belong to the class of linear models and thus
the common adjustment by means of mmm is available. This test has the average best balanced power,
i.e. shows high power for either linear or plateau shapes. Of course it shows a reduced power, if one
knew a-priori that there is a linear relationship and one would only use a linear regression model. But
this is far from reality in pharmacology/toxicology, because the shape is the result of the bioassay, not an
a-priori assumption. Because of the rather high correlated model, this decline is acceptable compared to
the power gain and more precise interpretation of the likely shape alternative/model.
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Considering the doses as quantitative covariate levels, the Tukey test can be recom-
mended, even its joint test together with Williams-type contrasts using the R-package
tukeytrend.
Analyzing the BUN example shows the appropriateness of the Tukey-Williams joint test: although
the quantitative regression part does not show any monotonous increase, while at least a Williams contrast
(most in the alternative the contrast (1000 + 500)/2 − 0) shows a trend up to the reversal point at 500
mg/kg. The effect size is the means value difference-to-control (and the regression slope in the regression
part- not in the alternative) where the most in the alternative effect size is (y¯BUN1000 + y¯
BUN
500 )/2− y¯BUN0 ) =
2.8mg/dl with a lower limit of 1.8 mg/dL.
Table 1: Tukey-Williams Trend Test: BUN example
Model Test statistics p-value
Tukey: arithmetic -0.275 0.905
Tukey: ordinal 1.436 0.231
Tukey: ari-logarithmic 1.436 0.231
Williams: 1000− 0 0.219 0.760
Williams: (1000 + 500)/2− 0 6.525 < 0.0001
Williams: (1000 + 500 + 250)/3− 0 5.517 < 0.0001
Williams: (1000 + 500 + 250 + 125)/4− 0 5.472 < 0.0001
Williams: (1000 + 500 + 250 + 125 + 62.5)/5− 0 5.565 < 0.0001
The R-Code is quite simple using the package tukeytrend: first a simple linear model is fitted into
the object mod1. Its estimators are used in the function tukeytrendfit to perform the MaxT test using the
3 regression models (ari, ord, arilog) and the William contrasts (cytpe=Williams), where ddf uses the
empirical degree of freedom and vcov the sandwich variance estimator to be robust to heteroscedasticity.
In the object ex1 the function glht() (from the package multcomp) estimates the adjusted p-values, or even
better the simultaneous confidence limits for a potential monotonous increase of the BUN values with
dose (see the data and the executable R code in the Appendix).
A further underrated issue is the trend test when heteroscedasticity occur- this can lead to a bias. As long
as ni are not too small, the use of a sandwich variance estimator is recommended [16] (see the BUN
example above).
mod1 <- lm(BUN ~ dose, data=mm)
tw1 <- tukeytrendfit(mod1, dose="dose", ddf="residual",
scaling=c("ari", "ord", "arilog", "treat"),
ctype="Williams")\\
ex1<-summary(glht(tw1 mmm, tw1 mlf,vcov = sandwich, alternative="greater"))
An underrated fact: shape specificity
The shape of the dose-response dependence is the result of the experiment, rarely an a-priori assumption.
In addition to the existence of a global trend, the information on what shape of the dose-response depen-
dence exists is relevant once again. This is quite challenging.
Nevertheless, trend tests that are designed for a linear alternative, such as the CA test for proportions [5]
or the nonparametric Jonckheere-test [28], are widely used. This is disturbing, because one rarely wants
to test for linear trend exactly, and a loss of power occurs, e.g. if there is a plateau at high doses which
is not uncommon in pharmacology/toxicology. In the sense of an average high power for any mono-
tone shape, trend tests which are sensitive to several alternatives are to be preferred. These are e.g. the
Williams and Tukey tests demonstrated above whereby their joint test is best in pharmacology/toxicology
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from this point of view, sensitive to a wide range of alternatives, with still acceptable conservatism [41].
Notice, for some issues in toxicology it is unacceptable to infer global trend with the usual trend tests,
although there is a significant downturn at high doses. One connects trend with monotonous, and a down-
turn effect at high dose(s) is just not monotonous. Here you can use a combination of trend test and test
between control and high dose: as an intersection-union tests [33], an union-intersection test with the
complete power approach [24] or surprisingly just the simple pairwise (or contrast) test control vs. high
dose.
On the other hand, there are situations, like the muta-tox issue in in-vitro mutagenicity assay, which, de-
spite a possible down-turn at high doses, would still like to decide on global trend. The toxicologist would
simply follow a trend test up to the optical maximum effect (and ignore the higher doses). Statistically
correct this can be achieved by means of maxT-test over all possible maximum doses (ignoring the higher
ones) [9].
Trend tests in generalized linear models (GLM)
Another contradiction exists: most trend tests assume normally distributed, homoscedastic errors, but
most endpoints in pharmacology/toxicology are skewed distributed or are counts, proportions, time-to-
event variables [46]. One solution is the use of the GLM, where suitable link-functions are used to
transform the different endpoint types appropriately. This is a general but asymptotic approach, i.e. it
requires a very large sample size and can cause problems with the common small ni.
Proportions are quite common in pharmacology/toxicology, such as microscopic incidences or crude
mortality/ tumor rates. For both the Williams-trend test [20] and the Tukey test [24] related GLM-
modifications exist, whereas the add-1 correction for common-used small ni can be recommended to
control the α-level approximately [43]. Note two very different models. On the one hand, the occurrence
of a condition such as a tumor is recorded at the level of the experimental unit, e.g. the animal. On the
other hand, proportions are repeatedly recorded within an experimental unit, such as (e.g., the number of
micronucleated erythocytes per scored polychromatic erythrocytes within a single mouse in the in vivo
micronucleus assay [19]. In the latter case, a link function for overdispersion can be used, since pooling
the individual proportions within the experimental unit usually underestimates the variance.
Similarly, counts can be evaluated, such as number of micronuclei; also with or without modeling of
overdispersion [21]. Count data are particularly sensitive to the underlying assumption, e.g. for ties and
variance heterogeneity structure. The CRAN package cotram [45] offers flexible count transformation
models where count responses may arise from various and complex data-generating processes. Because
the endpoint are counts with some tied data, the Dunnett test assuming approximate normal distribution
is not appropriate here. Instead the cotram package [45] offers count transformation models, providing a
simple but flexible approach for the regression analysis of count responses arising from various, and pos-
sibly complex, data-generating processes. (Notice, also for continuous variables there are robust methods
with the most likely transformation model behind [22, 25]).
The above example with the total brood count in an aquatic assay on ceriodaphnia dubia with nitrofen [6]
is used to demonstrate this approach:
data("nitrofen", package="boot")
nitrofen$Conc<-as.factor(nitrofen$conc)
library(multcomp)
library(cotram)
NSH<-cotram(total~Conc, data=nitrofen,order=5)
WISH<-glht(NSH, linfct = mcp(Conc = "Williams"), alternative="less")
All Williams contrasts are seriously in the alternative, most is the contrast (310 + 235)/2 − 0 with
the effect size of an odds ratio, i.e. a significant decreasing trend exists. Notice, the count transformation
model belongs not directly to a GLM (here a negative binomial link function can be used). Attention
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Contrast Estimate SE Test statistics p-value
310− 0 -12.9 2.32 -5.56 < 0.0001
(310 + 235)/2− 0 -10.0 1.75 -5.75 < 0.0001
(310 + 235 + 160)/3− 0 -7.2 1.27 -5.68 < 0.0001
(310 + 235 + 160 + 80)/4− 0 -5.4 1.03 -5.28 < 0.0001
Table 2: Williams-type p-values for count transformation model
should be paid to the specificity of data, where near-to-zero counts occur frequently, especially in control.
Simple transformations may be appropriate here [27].
Multinomial vectors occur also, such as the differential blood count. There analysis is more complex
and related multiple contrast modifications are available [39].
Time-to-event data occur commonly, such as time-to-death or time-to-tumor occurrence in long-term
carcinogenicity assays. These survival functions can be compared by the Williams-trend test assuming a
Cox proportional hazard model [15].
Because of their high toxicological relevance, the evaluation of graded histopathological findings (with
severity scores) is particularly interesting. Very different models can be helpful, especially if near-to-zero
categories occur in the control: collapsing categories [12] (or a closed permutation test [21], Chapter
2.1.8.1), cumulative link model for ordinal endpoints citeHothorn2016, Freeman-Tukey transformation
models or nonparametric contrast tests using the relative effect size estimator (see the section below).
Due to the complex interaction between tumor development and mortality, the evaluation of crude tumor
rates can be biased. Therefore, a mortality-adjusted analysis is indicated, relatively simple on the basis
of poly-k estimators, which do not need the cause of death. Individual weights wij = (tij/tmax)
k
considering the individual mortality pattern are used where tij is time of death of animal j in dose i and
the tuning parameter k is data-dependent. The weights result in adjusted sample sizes n∗i =
∑ni
j=1 wij to
be used instead of the randomized number of animals ni. Therefore adjusted proportions p∗i = yi/n
∗
i are
used in the GLM instead of the crude tumor proportions pi = yi/ni. This procedure is available for the
Williams test [43] and the Tukey test [24].
As a somewhat extreme example of simultaneous inference, the tumor and mortality data of the US-NTP
study on the carcinogenic potential of methyleugenol for the incidence of skin fibromas used [2] (available
in the CRAN package MCPAN). Since dose either quantitative (Tukey) or qualitative (Williams) fits best,
or the tuning parameter k=3 or k=6, we use a max(maxT)-test on these ((3 + 3) ∗ 2) marginal models in
weighted GLM’s for an identity link for difference of weighted proportions to control:
me$weightpoly3[wt0] <- (me$death[wt0]/max(me$death))^3
me$weightpoly6[wt0] <- (me$death[wt0]/max(me$death))^6
fitpoly3 <- glm(tumour ~ dose, data=me, family=binomial(link="identity"),
weight=weightpoly3)
fitpoly6 <- glm(tumour ~ dose, data=me, family=binomial(link="identity"),
weight=weightpoly6)
library(tukeytrend)
ttpoly3 <- tukeytrendfit(fitpoly3, dose="dose",
scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
ttpoly6 <- tukeytrendfit(fitpoly6, dose="dose",
scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
compttpoly6 <- glht(model=ttpoly6$mmm, linfct=ttpoly6$mlf, alternative="greater")
tt36 <- combtt(ttpoly3,ttpoly6)
TT36 <- summary(asglht(tt36, alternative="greater"))
Most in the alternative is the plateau-type Williams contrast for poly-6 adjustment, where as the differ-
ence to poly-3 is tiny in this particular example.
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Table 3: Tukey-Williams-type trend test models for poly k=3 and k=6 in the skin fibroma tumor data
Poly-k Model Test statistic p-value
3 Tukey: arithmetic 1.77 0.0877
Tukey: ordinal 2.50 0.0181
Tukey: ari-logarithmic 2.48 0.0190
Williams 150− 0 1.91 0.0670
Williams (150 + 75)/2− 0 3.03 0.0041
Williams (150 + 75 + 37)/3− 0 3.83 0.0003
6 Tukey: arithmetic 2.32 0.0277
Tukey: ordinal 2.98 0.0048
Tukey: ari-logarithmic 2.96 0.0051
Williams 150− 0 2.08 0.0471
Williams (150 + 75)/2− 0 3.18 0.0025
Williams (150 + 75 + 37)/3− 0 3.97 0.0002
Trend tests when adjusting against covariate and secondary factors is required
Sometimes the consideration of a covariate, such as initial body weight, or an additional factor, such as
sex, is important. Name-giving tests, such as the CA test, are usually difficult to extend - in GLM this is
very easy [21]. A typical application is the evaluation of organ weights, where the body weight can be
modeled as covariates.
Trend tests in generalized linear mixed effect models (GLMM)
The heterogeneity between repeated times, between litter mates, between cages, between tanks in aquatox-
assays, the cells within the slides within the organ-specific samples of the Comet assay, or independent
repeated studies on a particular test substance can be modeled as a random factor and thus the hierarchy
of the different sources of variance can be reproduced correctly by GLMM. Such models are already
complex and data-dependent, sometimes numerically unstable, especially when only a few levels can be
considered.
Repeated bioassays are common for relevant chemicals by several sponsors, e.g. the glyphosate bioas-
says. Here, simplifying the crude proportions of four studies (abbreviated by A-D) for malign lymphoma
in male mice are considered [47]. Figure 2 shows considerable heterogeneity between the studies, not
Figure 2: Crude malign lymphoma tumor rates of 4 carcinogenicity assays on glyphosate in male mice
only with regard to the shape of the dose-response relationship, but also with regard to the spontaneous
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rates, especially with regard to the very different doses chosen - across orders of magnitude. This alone
makes the qualitative modeling of the dose (Williams test) less appropriate. Therefore, the regression ap-
proach according to Tukey is the method of choice here, whereby the heterogeneity between studies with
a GLMM is estimated. The function glmmPQL() provides a robust penalized quasi-likelihood approach
in GLMM (with the canonical link function binomial()) and the internal function lmer2lm() transforms
GLMM-objects to GLM objects within the multiple marginal model approach [35]- the basis for the
decisive function glht(mmm()) with in the package multcomp.
library(tukeytrend)
Lmic <- dosescalett(Lmice, dose="dose", scaling=c("ari", "ord", "arilog")) data
glmmari <- glmmPQL(fixed=cbind(tumor,mice-tumor) ~ doseari, random = ~ 1 +doseari |study,
family = binomial, data=Lmic)
glmmord <- glmmPQL(fixed=cbind(tumor,mice-tumor) ~ doseord, random = ~ 1 +doseari |study,
family = binomial, data=Lmic, niter = 100)
glmmarilog <- glmmPQL(cbind(tumor,mice-tumor) ~ dosearilog, random = ~ 1 +doseari |study,
family = binomial, data=Lmic)
lmari <- tukeytrend:::lmer2lm(glmmari)
lmord <- tukeytrend:::lmer2lm(glmmord)
lmarilog <- tukeytrend:::lmer2lm(glmmarilog)
linf <- matrix(c(0,1), ncol=2)
ttglmm <- glht(mmm("mari"=lmari, "mord"=lmord, "marilog"=lmarilog),
mlf("mari"=linf, "mord"=linf, "marilog"=linf), alternative="greater")
Table 4: Odds ratios and their lower confidence limits using the Tukey trend test on crude malign lym-
phoma tumor rates of 4 carcinogenicity assays
Model Odds ratio Lower confidence limit
Tukey: arithmetic 1.000 0.999
Tukey: ordinal 1.071 0.976
Tukey: ari-logarithmic 1.214 0.960
For none of the 3 regression models is the lower limit greater than 1, i.e. there is no increasing trend,
which is not surprising given these pronounced heterogeneities.
Use the modifications of the Tukey-Williams joint test for non-normal endpoints and/or
complex designs in the generalized linear (mixed effects) model.
Nonparametric trend tests
Since the normal distribution assumption cannot be tested because of the small ni, nor can it be derived
from historical controls, nonparametric trend tests are often used, especially the Jonckheere-test and the
global-ranking version of the Williams test [44]. For tied values (see above the graded findings), and for
the usual heterogeneous variances, these tests are problematic. As an alternative, non-parametric tests
for relative effect size can be used, which are also available for multiple contrast tests and thus as a
modification of the Williams test [31]. A corresponding CRAN package nparcomp [32] is easily used for
this purpose.
Effect measures and their confidence interval
If one follows the recommendation to avoid p-values for the interpretation of trend tests, and instead to use
effect size estimates adapted to the toxicological problem and its intervals (confidence intervals or rather
compatibility intervals [23]), then the choice of a suitable effect size estimate is of primary importance.
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This contradicts the dominant choice of the difference-to-control as an effect size estimator. But there
are much more effect sizes. One of them has to do with the scale of the response variable, e.g. the risk
ratio for proportions or hazard rate for time-to-event variables. On the other hand, the effect size can
significantly define the modeling objective, such as ratio-to-control or odds ratio for continuous outcome
logistic regression [22].
Using ratio-to-control instead of the common-used difference-to-control
Difference-to-control is the mostly used effect size, mostly hidden, because their confidence intervals are
not explicitly interpreted, but simply the p-values. Sometimes one wants to interpret ratio-to-control, such
as the k-fold rule of the Ames assay. The usual procedure of log transformation of the response variable
can be problematic [38]. Instead, a direct modification of the Williams test is available for normally
distributed, even heteroscedastic errors [18] (numerically easily available in the package mratios, [10]).
In most cases the interpretation of a percentage change in pharmacology/toxicology is appropriate, but
not for very small near-to-zero values in the control.
Select effect sizes that are biologically appropriate and interpretable.
Further trend test issues
Phase IIb randomized clinical dose-finding trials (RCT) are similar to the above assays, with the rather
fewer doses (k=2, 3) arguing for low-parameter models [37]. The common-used MCP-Mod approach
represents a hybrid method consisting of contrast tests and related nonlinear models [34].
Sometimes, after detecting a trend, one wants to determine a specific experimental dose, such as minimal
effective dose (MED) in RCT or no-observed adverse event level (NOEAL) (in toxicology). In doing so,
one should pay attention to a possible bias due to the pooling properties of the trend tests.
We had only assumed randomized dose groups, but sometimes a trend was observed in continuous expo-
sure, e.g. transforming into groups via post-hoc categorization which may be misleading [13].
Sometimes you want to show that no trend exists. This cannot be done simply by a non-significant trend
test, since ’absence of evidence is no evidence of absence’ [4]. Instead, one tests the slope parameter for
non-inferiority, whereby the determination of the threshold limit is a delicate problem.
Conclusions
Trend tests sensitive to many possible shapes, considering dose qualitatively or quantitatively (or best
jointly), formulating for a single, interpretable parameter, in the same (or similar) framework for as many
effect sizes (and its confidence limits) and thus variable types as possible are available nowadays- a me-
thodical step forward. Not only the statistical methods are available, but also the corresponding software
in form of CRAN packages. A structure like a construction kit was described above, whereby real data
assays were evaluated exemplarily (further examples see [21, 23, 17, 24]).
The biggest limitation are the widely used small to very small ni, especially with often associated
unclear data conditions. Sometimes in these situations the use of simple transformations, such as arcsin
or FT, followed by the standard trend tests even makes sense - as least bad test.
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Appendix: Data and R-Code
############################# BUN example
mm <-
structure(list(BUN = c(15, 15.2, 14.9, 15.4, 16.8, 14.1, 14.9,
14.5, 13.7, 12.9, 15.8, 16.6, 12.7, 15.4, 14, 20.8, 19.1, 18.7,
18.8, 17.5, 21.9, 17.5, 21.3, 20.4, 18.2, 15.4, 15.2, 13, 14.7,
15.7, 15.7, 13.4, 15.1, 14.2, 15.2, 17.9, 18.2, 21.8, 18.2, 15.6,
22.3, 18.6, 22, 19.9, 19.6, 21, 21.7, 19.7, 18.8, 18.6, 14.9,
15.2, 15.2, 12.4, 13.7, 14.2, 15, 14.5, 16.3, 17.1),
Dose = structure(c(1L,1L, 1L, 1L, 1L, 1L, 1L, 1L, 1L, 1L,
2L, 2L, 2L, 2L, 2L, 2L, 2L,2L, 2L, 2L,
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3L, 3L, 3L, 3L, 3L, 3L, 3L, 3L, 3L, 3L,
4L, 4L, 4L, 4L, 4L, 4L, 4L, 4L, 4L, 4L,
5L, 5L, 5L, 5L, 5L, 5L, 5L, 5L, 5L, 5L,
6L, 6L, 6L, 6L, 6L, 6L, 6L, 6L, 6L, 6L),
.Label = c("0", "62.5", "125", "250", "500", "1000"),
class = "factor")), row.names = c(NA,-60L), class = "data.frame")
library("toxbox")
boxclust(data=mm, outcome="BUN", treatment="Dose", cluster=NULL,
ylabel="BUN", xlabel="Dose", option="uni", psize=1.1,nsize=2.5,
hjitter=0.3, legpos="none", printN="FALSE", white=TRUE, titlesize=8, labelsize=6)
###########################
library(tukeytrend)
library(multcomp)
library(sandwich)
mm$dose<-as.numeric(as.character(mm$Dose))
mod1 <- lm(BUN ~ dose, data=mm)
tw1 <- tukeytrendfit(mod1, dose="dose", ddf="residual",
scaling=c("ari", "ord", "arilog", "treat"),
ctype="Williams")
ex1<-summary(glht(tw1$mmm, tw1$mlf,vcov = sandwich, alternative="greater"))
T1<-fortify(summary(ex1))[, c(1,5,6)]
colnames(T1)<-c("Model","Test stats", "$p$-value")
library(xtable)
print(xtable(T1, digits=3, caption="Tukey-Williams Trend Test", label="tab:wuL"),
include.rownames=FALSE, caption.placement = "top", sanitize.text.function = function(x){x})
############################### nitrofen example
data("nitrofen", package="boot") # total brood
nitrofen
library(toxbox)
boxclust(data=nitrofen, outcome="total", treatment="conc", xlabel="Nitrofen concentration",
ylabel="Total brood number", psize=1.15, hjitter=0.15, vlines="fg", white=TRUE, printN=FALSE, legpos="none")
nitrofen$Conc<-as.factor(nitrofen$conc)
library(multcomp)
library(cotram)
NSH<-cotram(total~Conc, data=nitrofen,order=5)
WISH<-glht(NSH, linfct = mcp(Conc = "Williams"), alternative="less")
library(xtable)
library(ggplot2)
wish<-fortify(summary(WISH))
print(xtable(wish, caption="Williams-type p-values for count transformation model",
caption.placement = "top", digits=4))
########### poly3- poly-6 example
library(MCPAN)
data("methyl", package="MCPAN")
data(methyl)
me <- methyl
# death: time of death, max(death)=length of study = 730 days
# poly-3 adjustment: (time of death/max(time))^k, k=3,
#for those animals without tumour at time of death!
# Compute the poly-3 (-k)- weights at the level of single animals
me$weightpoly3 <- 1
me$weightpoly6 <- 1
# Animals without tumour at time of death get corrected sample size
wt0 <- which(me$tumour == 0)
me$weightpoly3[wt0] <- (me$death[wt0]/max(me$death))^3
me$weightpoly6[wt0] <- (me$death[wt0]/max(me$death))^6
me$dosegroup <- me$group
levels(me$dosegroup) <- c("0", "37", "75", "150")
me$dose <- as.numeric(as.character(me$dosegroup))
# Notice, the Modell use an identity link for difference to control,
fitpoly3 <- glm(tumour ~ dose, data=me, family=binomial(link="identity"),
weight=weightpoly3)
fitpoly6 <- glm(tumour ~ dose, data=me, family=binomial(link="identity"),
weight=weightpoly6)
library(tukeytrend)
ttpoly3 <- tukeytrendfit(fitpoly3, dose="dose",
scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
ttpoly6 <- tukeytrendfit(fitpoly6, dose="dose",
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scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
compttpoly6 <- glht(model=ttpoly6$mmm, linfct=ttpoly6$mlf, alternative="greater")
tt36 <- combtt(ttpoly3,ttpoly6)
TT36 <- summary(asglht(tt36, alternative="greater"))
library("ggplot2")
library(xtable)
polyk36<-fortify(TT36) [, c(1,5,6)]
colnames(polyk36)<-c("Comparisons","Test stats", "p-value")
print(xtable(polyk36, digits=c(0,0,2,4), caption="Tukey-Williams-type trend test models for poly k=3 and k=6", label="tab:exa14"),caption.placement = "top", include.rownames=FALSE)
####################################repeated glyphosat example
Lmice <- data.frame(
study=c(rep("A",4), rep("B",4),rep("C",4), rep("D",4)),
dose = c(0, 157, 814, 4841, 0,100,300,1000,
0, 165, 838, 4348, 0,71,234, 810),
Wscore=c("C","D1","D2","D2", "C","D1","D2","D2", "C","D1","D2","D2", "C","D1","D2","D3"),
tumor = c(2,5,4,2, 4,2,1,6,2,2,0,6,0,1,2,5),
mice = c(48,49,50,49,50,50,50,50, 50,50,50,50,51,51,51,51))
library(xtable)
LMI<-xtable(Lmice, digits=c(0,1,0,0,0,0))
print(LMI, include.rownames=FALSE,
caption.placement = "top",size="\\footnotesize")
library(ggplot2)
ggplot(Lmice, aes(y=tumor/mice, x=dose)) + geom_point(aes(color=study)) +
geom_line(aes(color=study, group=study)) +
scale_x_continuous(trans="sqrt",breaks=c(0,100,200,400,800,1600,5000))
library(tukeytrend)
Lmic <- dosescalett(Lmice, dose="dose", scaling=c("ari", "ord", "arilog"))$data
glmmari <- glmmPQL(fixed=cbind(tumor,mice-tumor) ~ doseari, random = ~ 1 +doseari |study,
family = binomial, data=Lmic)
glmmord <- glmmPQL(fixed=cbind(tumor,mice-tumor) ~ doseord, random = ~ 1 +doseari |study,
family = binomial, data=Lmic, niter = 100)
glmmarilog <- glmmPQL(cbind(tumor,mice-tumor) ~ dosearilog, random = ~ 1 +doseari |study,
family = binomial, data=Lmic)
lmari <- tukeytrend:::lmer2lm(glmmari)
lmord <- tukeytrend:::lmer2lm(glmmord)
lmarilog <- tukeytrend:::lmer2lm(glmmarilog)
linf <- matrix(c(0,1), ncol=2)
ttglmm <- glht(mmm("mari"=lmari, "mord"=lmord, "marilog"=lmarilog),
mlf("mari"=linf, "mord"=linf, "marilog"=linf), alternative="greater")
l2<-summary(ttglmm)
CIG<-confint(ttglmm)
cigg<-CIG$confint
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